Neon Ther­a­peu­tics bags a $70M round for ear­ly-stage neoanti­gen re­search

Neoanti­gens emerged as one of the hot new trends in biotech R&D a lit­tle more than a year ago. Af­ter a slate of can­cer vac­cines had strug­gled and failed in the clin­ic, the idea that you could fash­ion a vac­cine di­rect­ly tar­get­ing an in­di­vid­ual pa­tient’s tu­mors be­came fash­ion­able in cer­tain seg­ments of the ven­ture com­mu­ni­ty. And a group of in­vestors has joined hands to fund the next stage of clin­i­cal de­vel­op­ment at Neon Ther­a­peu­tics with a hefty $70 mil­lion B round.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.